+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID04975152

Study of Cemiplimab Before Surgery for Stage I-II Merkel Cell Carcinoma and Advanced Cutaneous Squamous Cell Carcinoma to Assess Safety and Biomarkers

Led by H. Lee Moffitt Cancer Center and Research Institute · Updated on 2026-06-25

36

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of cemiplimab given before surgery in treating patients with Merkel Cell Carcinoma or Cutaneous Squamous Cell Carcinoma CSCC. This phase 1 clinical trial focuses on patients with newly diagnosed or recurrent stage I-II Merkel Cell Carcinoma and locoregionally advanced CSCC. The study aims to understand how cemiplimab works as a neoadjuvant therapy and analyze related biomarkers. Participants will receive cemiplimab 350 mg intravenously at least three weeks before their tumor removal surgery. After surgery, they will continue to receive the same dose every three weeks for up to eight additional doses. This treatment plan spans several cycles, with doses given before and after surgery to study its effects on the cancer and patient safety. During the study, participants will be closely monitored through various assessments including laboratory tests, physical exams, and follow-up visits for up to three years. Researchers will track adverse events related to the treatment, relapse-free survival, and overall survival. Participants will be required to comply with study procedures and attend scheduled visits to ensure safety and accurate data collection throughout the trial period.

CONDITIONS

Brief Title

Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here